ArticleOncoTargets and therapy2017
Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Role of long non-coding RNAs in cholangiocarcinoma: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Prognostic and Clinicopathological Significance of Long Non-coding RNA PANDAR Expression in Cancer Patients: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Long non-coding PANDAR as a novel biomarker in human cancer: A systematic review.Cell proliferation · 2018Pooled it
- The Long Noncoding RNA PANDAR as a Prognostic and Diagnostic Biomarker in Panceratic Cancer.Current cancer drug targets · 2025Review
- The Diagnostic and Prognostic Potentials of Non-Coding RNA in Cholangiocarcinoma.International journal of molecular sciences · 2024Review
- The long non-coding RNA PANDAR regulates cell proliferation and epithelial-to-mesenchymal transition in glioma.Histology and histopathology · 2023Article
- Review
- Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma.Frontiers in cell and developmental biology · 2022Review
- Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic lncRNA Signature in Bladder Cancer.Frontiers in oncology · 2021Article
- Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.Frontiers in oncology · 2021Review
- Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.Cancer communications (London, England) · 2020Review
- Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review.Journal of clinical medicine · 2020Review
- Upregulated Long Noncoding RNA LINC01234 Predicts Unfavorable Prognosis for Colorectal Cancer and Negatively Correlates With KLF6 Expression.Annals of laboratory medicine · 2020Article
- Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p.Journal of cellular and molecular medicine · 2019Article
- LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer.Scientific reports · 2019Article
- The Interaction Between lncRNA SNHG1 and miR-140 in Regulating Growth and Tumorigenesis via the TLR4/NF-κB Pathway in Cholangiocarcinoma.Oncology research · 2019Article
- Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.Cellular and molecular life sciences : CMLS · 2019Review
- Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- lncRNAs as potential molecular biomarkers in the clinicopathology and prognosis of cholangiocarcinoma: a systematic review and meta-analysis.OncoTargets and therapy · 2019Review
- Up-regulated LncRNA-ATB regulates the growth and metastasis of cholangiocarcinoma via miR-200c signals.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is one of the most malignant human cancers with increasing incidence worldwide. LncRNAs have emerged as gene regulators and prognostic biomarkers in a variety of neoplasms. PANDAR, a novel cancer-related lncRNA, has been reported to be upregulated in diverse human carcinomas. In this study, we aimed to investigate the clinical significance of lncRNA PANDAR in CCA and explore its functional roles in CCA cells including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). The results showed that PANDAR was significantly upregulated in CCA tissue specimens and cell lines, and its high expression was closely associated with lymph node invasion (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.